

Epinephrine Auto-Injector Market - Global Outlook and Forecast 2020-2025

<https://marketpublishers.com/r/E9823EAAA5C7EN.html>

Date: April 2020

Pages: 233

Price: US\$ 3,500.00 (Single User License)

ID: E9823EAAA5C7EN

Abstracts

With the Purchase of Global Epinephrine Auto-Injector Market Report, Receive a FREE Copy of Market Impact of COVID-19 on Businesses.

The epinephrine auto-injector market is expected to grow at a CAGR of over 8% during the period 2019–2025.

The global epinephrine auto-injector market is expected to grow at a steady rate during the forecast period. The growth can be mainly attributed to the growing prevalence of anaphylaxis across demographics. Anaphylaxis is characterized as a potentially life-threatening systemic allergic reaction, which is most commonly triggered by medication, food allergies, or insect stings. In developed countries such as the US and the UK, the incidence of anaphylaxis is 40–500 per million persons. Anaphylaxis-associated mortality is estimated at 0.63–0.76 per million. In the US, up to 5% population suffers from this condition. Over the last several years, a rising number of clinical databases such as PubMed have captured the growing prevalence of anaphylaxis. Globally, allergies caused by food items, food additives, latex, and dust are increasing at a steady rate. Such allergies, including anaphylaxis, are the most commonly prevalent in industrially developed countries such as the US and the UK. Therefore, the growing incidence of anaphylaxis is likely to increase the high uptake of epinephrine as it the first-aid treatment option, thereby driving the global market.

The following factors are likely to contribute to the growth of the epinephrine auto-injector market during the forecast period:

Emergence of Innovative Solutions for Anaphylaxis Management

Increasing Demand for Generic Epinephrine Auto-injectors at
Pharma/Retail Stores

Growing Demand for Self-administration of Drugs

Availability of Generic Versions of Auto-injectors

The study considers the present scenario of the epinephrine auto-injector market and its market dynamics for the period 2019-2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The study offers both the demand and supply aspect of the market. It profiles and examines leading companies and other prominent companies operating in the market.

EPINEPHRINE AUTO-INJECTOR MARKET: SEGMENTATION

This research report includes a detailed segmentation by dosage, age group, end-user, and geography. The growing incidence of anaphylaxis in adults, especially in the elderly population, is the primary factor driving the growth of the high dose segment. As epinephrine is considered as the first-line treatment for anaphylaxis, the increasing recommendation of high dose by healthcare professionals (HCP) across the globe for adult patients is fueling the growth of the segment. Moreover, market players are also focusing on providing generic, low-cost products, which are increasing the demand for affordable treatment options for managing anaphylactic reactions.

Several social and emotional factors contribute to the high prevalence of anaphylaxis in teenage and adult groups, including risk-taking behaviors with eating and disease denial. Adults with peanut allergy have more severe reactions than children. HCPs recommend a high as well as safe dose (usually 0.3 mg) of epinephrine auto-injectors to the patient group aged 12 years and above. Furthermore, anaphylaxis in the elderly population tends to be life-threatening and requires intensified medical intervention. Therefore, managing the high risk of anaphylaxis in this group, especially in elderly people, is expected to drive the uptake of epinephrine auto-injectors.

The burden of anaphylaxis among children is growing, hence it requires quick and effective management. Government and regulatory bodies are providing safeguards to prevent fatal reactions among children in the 6–12 years age group. Epinephrine through auto-injectors acts fast and can rapidly treat the most dangerous symptoms in children, including throat swelling, difficulty breathing, and low blood pressure. Thus, it

is always been recommended to make ready epinephrine auto-injectors for children in schools to avoid fatal conditions due to anaphylaxis, thereby driving the segment growth.

In 2019, the below 6 years segment accounted for a 10% market share of the global epinephrine auto-injector market. Children in this age group are prescribed to be treated with 0.15 mg/0.1 mg dose capacity. An estimated 130% increase in emergency room visits for anaphylaxis among children aged 4 years old and younger reported between 2005 and 2014. Since the management of anaphylaxis in this age group is becoming a major concern among HCPs and parents, vendors are focusing on introducing low-cost epinephrine auto-injectors for this age group.

The individual end-user segment accounted for the highest share in 2019. The segment is likely to grow with the highest growth rate mainly due to the growing demand for self-management of anaphylaxis. Individuals carry epinephrine auto-injectors for the treatment of sudden anaphylaxis shock. As the prevalence is growing rapidly worldwide, self-management is becoming increasingly important. Hence, the segment is likely to emerge as a major revenue generator during the forecast period.

HCPs in hospitals & clinics are using epinephrine auto-injectors for the emergency management of anaphylaxis. The market is growing at a healthy rate on account of the high adoption of these devices by emergency departments in hospitals and clinics. The availability of skilled HCPs with knowledge and expertise also attracts many patients to hospitals and clinics. Large and medium-sized hospitals are equipped with sophisticated healthcare infrastructure for emergency management of anaphylaxis. Hence, the share of this segment is likely to grow at a steady growth during the forecast period.

Market Segmentation by Dosage

High

Low

Market Segmentation by Age Group

Below 6 Years

Between 6 & 12 years

Above 12 years

Market Segmentation by End-user

Hospitals & Clinics

Individuals

Others

INSIGHTS BY GEOGRAPHY

North America dominates the epinephrine auto-injector market. The presence of a large disease population, coupled with better access to treatment for anaphylaxis, is the primary factor for its high market share. The strong presence of key vendors is also another reason for high product uptake in the region. Moreover, the rise in the anaphylactic patient pool and the launch of generic substitutes, which help to treat the condition effectively in adults and children groups, are likely to boost the growth during the forecast period.

Europe is the second-largest market. Better disease awareness, high healthcare spending, and the presence of key vendors are the primary factors for high market shares. Germany, France, the UK, Spain, and the Netherlands are the major revenue contributors to the region. The Europe market is likely to be driven by the increasing treatment-seeking population due to increased awareness of anaphylactic reactions.

Japan, Australia, and South Korea are the major revenue contributors in APAC for epinephrine auto-injectors. A low treatment-seeking population associated with social stigma in select regions, low awareness and comparatively minimal access to healthcare services, especially in developing countries are a few factors that limit growth potential in the region. However, the growth in disease prevalence, improvement in healthcare spending, increase in awareness for food allergies, including anaphylaxis, are expected to fuel the growth in the region.

Market Segmentation by Geography

Europe

Spain

Germany

Netherlands

France

UK

North America

US

Canada

APAC

South Korea

Japan

Australia

Latin America

Brazil

Argentina

MEA

Turkey

Israel

South Africa

INSIGHTS BY VENDORS

The global epinephrine auto-injector market is highly consolidated and is characterized by the presence of a few established vendors holding the majority of the market share. Vendors are offering several branded as well as generic epinephrine auto-injectors and are competing based on factors in terms of regulatory approvals, safety features, accurate dosing, convenience, technology, marketing strategies, and distribution channels.

Key Vendors

Mylan

Teva Pharmaceutical Industries

Amneal Pharmaceuticals

Other Vendors

Adamis Pharmaceuticals

ALK-Abell?

Bioprojet PHARMA

Bausch & Lomb

kal?o

Novartis

KEY MARKET INSIGHTS

The analysis of the epinephrine auto-injector market provides sizing and growth opportunities for the period 2019–2025.

Offers sizing and growth prospects of the market for the forecast period 2020–2025.

Provides comprehensive insights on the latest industry trends, forecast, and growth drivers in the market.

Includes a detailed analysis of growth drivers, challenges, and investment opportunities.

Delivers a complete overview of segments and the regional outlook of the market.

Offers an exhaustive summary of the vendor landscape, competitive analysis, and key strategies to gain competitive advantage.

Contents

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

4.1 Market Definition

4.1.1 Inclusion

4.1.2 Exclusion

4.2 Base Year

4.3 Scope of The Study

4.4 Market Segments

4.4.1 Market Segmentation by Dosage

4.4.2 Market Segmentation by Age Group

4.4.3 Market Segmentation by End-user

4.4.4 Market Segmentation by Geography

5 REPORT ASSUMPTIONS & CAVEATS

5.1 Key Caveats

5.2 Currency Conversion

5.3 Market Derivation

6 MARKET AT A GLANCE

7 INTRODUCTION

7.1 Anaphylaxis: Overview

7.1.1 Background

7.1.2 Epinephrine Auto-injectors for the Treatment of Anaphylaxis

7.2 Epinephrine Auto-injectors Market Snapshot

8 MARKET OPPORTUNITIES & TRENDS

8.1 Emergence Of Innovative Solutions For Anaphylaxis Management

8.2 Vendors' Growing Focus On Patient Assistance Programs

8.3 Increasing Demand For Generic Epinephrine Auto-Injectors At Pharma/Retail Stores

9 MARKET GROWTH ENABLERS

9.1 Rising Incidence Of Anaphylaxis

9.2 Growing Demand For Self-Administration Of Drugs

9.3 Availability Of Generic Versions Of Auto-Injectors

10 MARKET RESTRAINTS

10.1 Presence of Alternative Treatment Options

10.2 Adverse Side Effects Associated With Epinephrine Auto-Injectors

10.3 Shortage of Epinephrine Auto-Injectors

10.4 High Cost of Epinephrine Auto-Injectors

11 MARKET LANDSCAPE

11.1 Market Overview

11.2 Market Size & Forecast

11.3 Five Forces Analysis

11.3.1 Threat of New Entrants

11.3.2 Bargaining Power of Suppliers

11.3.3 Bargaining Power of Buyers

11.3.4 Threat of Substitutes

11.3.5 Competitive Rivalry

12 DOSAGE

12.1 Market Snapshot & Growth Engine

12.2 Market Overview

12.3 High Dose

12.3.1 Market Overview

12.3.2 Market Size & Forecast

12.4 Low Dose

12.4.1 Market Overview

12.4.2 Market Size & Forecast

13 AGE GROUP

13.1 Market Snapshot & Growth Engine

13.2 Market Overview

13.3 Above 12 Years

13.3.1 Market Overview

13.3.2 Market Size & Forecast

13.4 6-12 Years

13.4.1 Market Overview

13.4.2 Market Size & Forecast

13.5 Below 6 Years

13.5.1 Market Overview

13.5.2 Market Size & Forecast

14 END-USER

14.1 Market Snapshot & Growth Engine

14.2 Market Overview

14.3 Individuals

14.3.1 Market Overview

14.3.2 Market Size & Forecast

14.4 Hospitals & Clinics

14.4.1 Market Overview

14.4.2 Market Size & Forecast

14.5 Others

14.5.1 Market Overview

14.5.2 Market Size & Forecast

15 GEOGRAPHY

15.1 Market Snapshot & Growth Engine

15.2 Geographic Overview

16 NORTH AMERICA

16.1 Market Overview

16.2 Market Size & Forecast

16.3 North America: Dosage Segmentation

16.3.1 Market Snapshot & Growth Engine

16.4 Key Countries

16.4.1 US: MARKET SIZE & FORECAST

16.4.2 Canada: MARKET SIZE & FORECAST

17 EUROPE

17.1 Market Overview

17.2 Market Size & Forecast

17.3 Europe: Dosage Segmentation

17.3.1 Market Snapshot & Growth Engine

17.4 Key Countries

17.4.1 Germany: Market Size & Forecast

17.4.2 France: Market Size & Forecast

17.4.3 UK: Market Size & Forecast

17.4.4 Spain: Market Size & Forecast

17.4.5 Netherlands: Market Size & Forecast

18 APAC

18.1 Market Overview

18.2 Market Size & Forecast

18.3 APAC: Dosage Segmentation

18.3.1 Market Snapshot & Growth Engine

18.4 Key Countries

18.4.1 Japan: Market Size & Forecast

18.4.2 Australia: Market Size & Forecast

18.4.3 South Korea: Market Size & Forecast

19 MIDDLE-EAST & AFRICA

19.1 Market Overview

19.2 Market Size & Forecast

19.3 Middle-East & Africa: Dosage Segmentation

19.3.1 Market Snapshot & Growth Engine

19.4 Key Countries

19.4.1 Israel: Market Size & Forecast

19.4.2 South Africa: Market Size & Forecast

19.4.3 Turkey: Market Size & Forecast

20 LATIN AMERICA

- 20.1 Market Overview
- 20.2 Market Size & Forecast
- 20.3 Latin America: Dosage Segmentation
 - 20.3.1 Market Snapshot & Growth Engine
- 20.4 Key Countries
 - 20.4.1 Brazil: Market Size & Forecast
 - 20.4.2 Argentina: Market Size & Forecast

21 COMPETITIVE LANDSCAPE

- 21.1 Competition Overview
- 21.2 Market Share Analysis
 - 21.2.1 Mylan
 - 21.2.2 Teva Pharmaceutical Industries
 - 21.2.3 Amneal Pharmaceuticals
 - 21.2.4 Adamis Pharmaceuticals
 - 21.2.5 ALK-Abell?
 - 21.2.6 Bausch & Lomb
 - 21.2.7 BIOPROJET PHARMA
 - 21.2.8 kal?o
 - 21.2.9 Novartis

22 KEY COMPANY PROFILES

- 22.1 Mylan
 - 22.1.1 Business Overview
 - 22.1.2 Product Offerings
 - 22.1.3 Key Strategies
 - 22.1.4 Key Strengths
 - 22.1.5 Key Opportunities
- 22.2 Teva Pharmaceutical Industries
 - 22.2.1 Business Overview
 - 22.2.2 Product Offerings
 - 22.2.3 Key Strategies
 - 22.2.4 Key Strengths
 - 22.2.5 Key Opportunities
- 22.3 Amneal Pharmaceuticals
 - 22.3.1 Business Overview

- 22.3.2 Product Offerings
- 22.3.3 Key Strategies
- 22.3.4 Key Strengths
- 22.3.5 Key Opportunities

23 OTHER PROMINENT VENDORS

23.1 Adamis Pharmaceuticals

- 23.1.1 Business Overview
- 23.1.2 Product Offerings
- 23.1.3 Key Strategies
- 23.1.4 Key Strengths
- 23.1.5 Key Opportunities

23.2 ALK-Abell?

- 23.2.1 Business Overview
- 23.2.2 Product Offerings
- 23.2.3 Key Strategies
- 23.2.4 Key Strengths
- 23.2.5 Key Opportunities

23.3 BIOPROJET PHARMA

- 23.3.1 Business Overview
- 23.3.2 Product Offerings
- 23.3.3 Key Strategies
- 23.3.4 Key Strengths
- 23.3.5 Key Opportunities

23.4 Bausch & Lomb

- 23.4.1 Business Overview
- 23.4.2 Product Offerings
- 23.4.3 Key Strategies
- 23.4.4 Key Strengths
- 23.4.5 Key Opportunities

23.5 kal?o

- 23.5.1 Business Overview
- 23.5.2 Product Offerings
- 23.5.3 Key Strategies
- 23.5.4 Key Strengths
- 23.5.5 Key Opportunities

23.6 Novartis

- 23.6.1 Business Overview

23.6.2 Product Offerings

23.6.3 Key Strategies

23.6.4 Key Strengths

23.6.5 Key Opportunities

24 REPORT SUMMARY

24.1 Key Takeaways

24.2 Strategic Recommendations

25 QUANTITATIVE SUMMARY

25.1 Dosage

25.2 Age Group

25.3 End-User

25.4 Geography

25.5 North America: Dosage Segmentation

25.6 Europe: Dosage Segmentation

25.7 APAC: Dosage Segmentation

25.8 Middle East & Africa: Dosage Segmentation

25.9 Latin America: Dosage Segmentation

26 APPENDIX

26.1 Abbreviations

List Of Exhibits

LIST OF EXHIBITS

- Exhibit 1 Segmentation of Global Epinephrine Auto-injectors Market
- Exhibit 2 Market Size Calculation Approach 2019
- Exhibit 3 Major Symptoms of Anaphylaxis
- Exhibit 4 Most Common Triggers of Anaphylaxis
- Exhibit 5 Conditions where Epinephrine Auto-injectors are Used for Children Include
- Exhibit 6 Major Market Dynamics of Global Epinephrine Auto-injectors Market
- Exhibit 7 Global Epinephrine Auto-injectors Market by Geography 2019 (%)
- Exhibit 8 Global Epinephrine Auto-injectors Market by Dosage 2019 (%)
- Exhibit 9 Impact of Emergence of Innovative Solutions for Anaphylaxis Management
- Exhibit 10 Impact of Vendors' Growing Focus on Patient Assistance Programs
- Exhibit 11 Mylan's Patient Assistance Program Snapshot
- Exhibit 12 Impact of Increasing Demand for Generic Epinephrine Auto-injectors at Pharma/Retail Stores
- Exhibit 13 Impact of Rising Incidence of Anaphylaxis
- Exhibit 14 Anaphylaxis Epidemiology 2000?2015
- Exhibit 15 Hospital Admissions for All-cause Anaphylaxis (%)
- Exhibit 16 Implications for Fatal Drug Anaphylaxis
- Exhibit 17 Impact of Growing Demand for Self-administration of Drugs
- Exhibit 18 Risk Factors to Consider Using Self-injectable Epinephrine
- Exhibit 19 Impact of Availability of Generic Versions of Auto-injectors
- Exhibit 20 Overview of Generic and Branded EpiPen Version
- Exhibit 21 Impact of Presence of Alternative Treatment Options
- Exhibit 22 Popular Alternative Methods for Anaphylaxis Treatment
- Exhibit 23 Impact of Adverse Side Effects Associated with Epinephrine Auto-injectors
- Exhibit 24 Common Side Effects of Epinephrine Auto-injectors
- Exhibit 25 Some Rare Side-effects of Epinephrine
- Exhibit 26 Adverse Effects of Epinephrine on Organs & Tissues
- Exhibit 27 Impact of Shortage of Epinephrine Auto-injectors
- Exhibit 28 Impact of High Cost of Epinephrine Auto-injectors
- Exhibit 29 Average Price of Key Epinephrine Auto-injectors
- Exhibit 30 Global Epinephrine Auto-injectors Market 2019–2025 (\$ million)
- Exhibit 31 Global Epinephrine Auto-injectors Market by Geography
- Exhibit 32 Global Epinephrine Auto-injectors Market by Dosage
- Exhibit 33 Global Epinephrine Auto-injectors Market by Age Group
- Exhibit 34 Global Epinephrine Auto-injectors Market by End-user

- Exhibit 35 Five Forces Analysis 2019
- Exhibit 36 Incremental Growth by Dosage 2019 & 2025
- Exhibit 37 Global Epinephrine Auto-injectors Market by Dosage
- Exhibit 38 Global Epinephrine Auto-injectors Market by Dosage: Incremental Growth
- Exhibit 39 Global Epinephrine Auto-injectors Market by Dosage: Absolute Growth
- Exhibit 40 Global Epinephrine Auto-injectors Market by Dosage 2019?2025 (\$ million)
- Exhibit 41 Global Epinephrine Auto-injectors Market by Dosage 2019?2025 (%)
- Exhibit 42 Global Epinephrine Auto-injectors Market by High Dose: Incremental and Absolute Growth
- Exhibit 43 Usage of High Dose Epinephrine Auto-injectors
- Exhibit 44 Global Epinephrine Auto-injectors Market by High Dose 2019–2025 (\$ million)
- Exhibit 45 Global Epinephrine Auto-injectors Market by Low Dose: Incremental & Absolute Growth
- Exhibit 46 Usage of Low Dose Epinephrine Auto-injectors
- Exhibit 47 Global Epinephrine Auto-injectors Market by Low Dose 2019–2025 (\$ million)
- Exhibit 48 Incremental Growth by Age Group 2019 & 2025
- Exhibit 49 Global Epinephrine auto-injectors market by Age Group
- Exhibit 50 Global Epinephrine Auto-injectors Market by Age Group: Incremental Growth
- Exhibit 51 Global Epinephrine Auto-injectors Market by Age Group: Absolute Growth
- Exhibit 52 Global Epinephrine Auto-injectors Market by Age Group 2019?2025 (\$ million)
- Exhibit 53 Global Epinephrine Auto-injectors Market by Age Group 2019?2025 (%)
- Exhibit 54 Global Epinephrine Auto-injectors Market for Above 12 Years: Incremental & Absolute Growth
- Exhibit 55 Yearly Prevalence of Emergent Patients with Anaphylaxis by Age Group 2010?2014
- Exhibit 56 Global Epinephrine Auto-injectors Market for Above 12 Years 2019–2025 (\$ million)
- Exhibit 57 Global Epinephrine Auto-injectors Market for 6?12 Years: Incremental & Absolute Growth
- Exhibit 58 Action of a Standard Epinephrine Auto-injector
- Exhibit 59 Global Epinephrine Auto-injectors Market for 6?12 Years 2019–2025 (\$ million)
- Exhibit 60 Global Epinephrine Auto-injectors Market for Below 6 Years: Incremental & Absolute Growth
- Exhibit 61 Global Epinephrine Auto-injectors Market for Below 6 Years 2019–2025 (\$ million)
- Exhibit 62 Incremental Growth by End-user 2019 & 2025

- Exhibit 63 Global Epinephrine Auto-injectors Market by End-user
- Exhibit 64 Global Epinephrine Auto-injectors Market by End-user: Incremental Growth
- Exhibit 65 Global Epinephrine Auto-injectors Market by End-user: Absolute Growth
- Exhibit 66 Global Epinephrine Auto-injectors Market by End-user 2019?2025 (\$ million)
- Exhibit 67 Global Epinephrine Auto-injectors Market by End-user 2019?2025 (%)
- Exhibit 68 Global Epinephrine Auto-injectors Market by Individuals: Incremental & Absolute Growth
- Exhibit 69 Global Epinephrine Auto-injectors Market by Individuals 2019–2025 (\$ million)
- Exhibit 70 Global Epinephrine Auto-injectors Market by Hospitals & Clinics: Incremental & Absolute Growth
- Exhibit 71 Global Epinephrine Auto-injectors Market by Hospitals & Clinics 2019–2025 (\$ million)
- Exhibit 72 Epinephrine Auto-injectors Market by Others: Incremental & Absolute Growth
- Exhibit 73 Global Epinephrine Auto-injectors Market by Others 2019–2025 (\$ million)
- Exhibit 74 Incremental Growth by Geography 2019 & 2025
- Exhibit 75 Global Epinephrine Auto-injectors Market by Geography
- Exhibit 76 Global Epinephrine Auto-Injectors Market by Geography 2019: Key Countries (\$ million)
- Exhibit 77 Global Epinephrine Auto-Injectors Market by Geography: Incremental Growth
- Exhibit 78 Global Epinephrine Auto-Injectors Market by Geography: Absolute Growth
- Exhibit 79 Global Epinephrine Auto-Injectors Market by Geography 2019?2025 (\$ million)
- Exhibit 80 Global Epinephrine Auto-Injectors Market by Geography 2019?2025 (%)
- Exhibit 81 Epinephrine Auto-Injectors Market in North America in 2019
- Exhibit 82 North America Epinephrine Auto-injectors Market: Incremental & Absolute Growth
- Exhibit 83 Epinephrine Auto-injectors Market in North America 2019–2025 (\$ million)
- Exhibit 84 Incremental Growth by Dosage 2019 & 2025
- Exhibit 85 North America Epinephrine Auto-injectors Market by Dosage 2019?2025 (\$ million)
- Exhibit 86 North America Epinephrine Auto-injectors Market by Dosage 2019?2025 (%)
- Exhibit 87 Incremental Growth in North America 2019 & 2025
- Exhibit 88 Epinephrine Auto-injectors Market in US 2019–2025 (\$ million)
- Exhibit 89 Epinephrine Auto-injectors Market in Canada 2019–2025 (\$ million)
- Exhibit 90 Epinephrine Auto-injectors Market in Europe 2019
- Exhibit 91 Europe Epinephrine Auto-injectors Market: Incremental & Absolute Growth
- Exhibit 92 Epinephrine Auto-injectors Market in Europe 2019–2025 (\$ million)
- Exhibit 93 Incremental Growth by Dosage 2019 & 2025

- Exhibit 94 Europe Epinephrine Auto-injectors Market by Dosage 2019?2025 (\$ million)
- Exhibit 95 Europe Epinephrine Auto-injectors Market by Dosage 2019?2025 (%)
- Exhibit 96 Incremental Growth in Europe 2019 & 2025
- Exhibit 97 Knowledge Distribution about Emergency Kit for Managing Anaphylaxis among Teachers and Child-care Providers in Germany
- Exhibit 98 Epinephrine Auto-injectors Market in Germany 2019–2025 (\$ million)
- Exhibit 99 Epinephrine Auto-injectors Market in France 2019–2025 (\$ million)
- Exhibit 100 Epinephrine Auto-injectors Market in UK 2019–2025 (\$ million)
- Exhibit 101 Epinephrine Auto-injectors Market in Spain 2019–2025 (\$ million)
- Exhibit 102 Epinephrine Auto-injectors Market in Netherlands 2019–2025 (\$ million)
- Exhibit 103 APAC Epinephrine Auto-injectors Market: Incremental & Absolute Growth
- Exhibit 104 Epinephrine Auto-injectors Market in APAC 2019 (\$ million)
- Exhibit 105 Epinephrine Auto-injectors Market in APAC 2019–2025 (\$ million)
- Exhibit 106 APAC Epinephrine Auto-injectors Market by Dosage 2019?2025 (\$ million)
- Exhibit 107 APAC Epinephrine Auto-injectors Market by Dosage 2019?2025 (%)
- Exhibit 108 Incremental Growth in APAC 2019 & 2025
- Exhibit 109 Epinephrine Auto-injectors Market in Japan 2019–2025 (\$ million)
- Exhibit 110 Epinephrine Auto-injectors Market in Australia 2019–2025 (\$ million)
- Exhibit 111 Epinephrine Auto-injectors Market in South Korea 2019–2025 (\$ million)
- Exhibit 112 Epinephrine Auto-injectors Market in Middle East & Africa 2019 (\$ million)
- Exhibit 113 Middle East & Africa Epinephrine Auto-injectors Market: Incremental & Absolute Growth
- Exhibit 114 Epinephrine Auto-injectors Market in Middle East & Africa 2019–2025 (\$ million)
- Exhibit 115 Middle East & Africa Epinephrine Auto-injectors Market by Dosage 2019?2025 (\$ million)
- Exhibit 116 Middle East & Africa Epinephrine Auto-injectors Market by Dosage 2019?2025 (%)
- Exhibit 117 Incremental Growth in Middle East & Africa 2019 & 2025
- Exhibit 118 Epinephrine Auto-injectors Market in Israel 2019–2025 (\$ million)
- Exhibit 119 Epinephrine Auto-injectors Market in South Africa 2019–2025 (\$ million)
- Exhibit 120 Epinephrine Auto-injectors Market in Turkey 2019–2025 (\$ million)
- Exhibit 121 Epinephrine Auto-injectors Market in Latin America 2019 (\$ million)
- Exhibit 122 Latin America Epinephrine Auto-injectors Market: Incremental & Absolute Growth
- Exhibit 123 Epinephrine Auto-injectors Market in Latin America 2019–2025 (\$ million)
- Exhibit 124 Latin America Epinephrine Auto-injectors Market by Dosage 2019?2025 (\$ million)
- Exhibit 125 Latin America Epinephrine Auto-injectors Market by Dosage 2019?2025 (%)

- Exhibit 126 Incremental Growth in Latin America 2019 & 2025
- Exhibit 127 Epinephrine Auto-injectors Market in Brazil 2019–2025 (\$ million)
- Exhibit 128 Epinephrine Auto-injectors Market in Argentina 2019–2025 (\$ million)
- Exhibit 129 Global Epinephrine Auto-injectors Market: Vendors Market Share (2019)
- Exhibit 130 Mylan: Sales by Geography 2019 (%)
- Exhibit 131 Teva Pharmaceutical Industries: Revenue by Segment 2017 & 2018 (\$ million)
- Exhibit 132 Adamis Pharmaceuticals: R&D Expenditure 2016?2018 (\$ million)
- Exhibit 133 ALK-Abell?: Revenue by Product Line 2017 & 2018 (\$ million)
- Exhibit 134 ALK-Abell?: Revenue by Geography 2018 (\$ million)
- Exhibit 135 Novartis: R&D Expenditure 2016?2018 (\$ million)
- Exhibit 136 Novartis: Revenue by Segment 2017 & 2018 (\$ million)

List Of Tables

LIST OF TABLES

Table 1 Key Caveats

Table 2 Currency Conversion 2013?2019

Table 3 Anaphylaxis Definitions Worldwide

Table 4 Major Epinephrine Auto-injectors Under Development

Table 5 Popular Patient Assistance Programs Offered by Vendors

Table 6 Potential Advantages of Intravenous Epinephrine Delivery for Anaphylaxis Treatment

Table 7 Global Epinephrine Auto-injectors Market by Dosage 2019?2025 (\$ million)

Table 8 Significant Players Offering High Dose Epinephrine Auto-injectors

Table 9 Significant Players Offering Low Dose Epinephrine Auto-injectors

Table 10 Global Epinephrine Auto-injectors Market by Age Group 2019?2025 (\$ million)

Table 11 Significant Players Offering Epinephrine Auto-injectors for Patients Above 12 Years

Table 12 Significant Players Offering Epinephrine Auto-injectors for Patients in the Age Group of 6?12 Years

Table 13 Significant Players Offering Epinephrine Auto-injectors for Below 6 Years Patient Group

Table 14 Global Epinephrine Auto-injectors Market by End-user 2019?2025 (\$ million)

Table 15 Global Epinephrine Auto-injectors Market by Geography 2019?2025 (\$ million)

Table 16 North America Epinephrine Auto-injectors Market by Dosage 2019?2025 (\$ million)

Table 17 Europe Epinephrine Auto-injectors Market by Dosage 2019?2025 (\$ million)

Table 18 Incremental Growth by Dosage 2019 & 2025

Table 19 APAC Epinephrine Auto-injectors Market by Dosage 2019?2025 (\$ million)

Table 20 Incremental Growth by Dosage 2019 & 2025

Table 21 Middle East & Africa Epinephrine Auto-injectors market by Dosage 2019?2025 (\$ million)

Table 22 Incremental Growth by Dosage 2019 & 2025

Table 23 Latin America Epinephrine Auto-injectors Market by Dosage 2019?2025 (\$ million)

Table 24 Competitive Structure Analysis of Global Epinephrine Auto-injectors Market 2019

Table 25 Global Epinephrine Auto-injectors Market: Vendor Ranking 2019

Table 26 Mylan: Major Product Offerings

Table 27 Teva Pharmaceutical Industries: Major Product Offerings

Table 28 Amneal Pharmaceuticals: Major Product Offerings

Table 29 Adamis Pharmaceuticals: Major Product Offerings

Table 30 ALK-Abell?: Major Product Offerings

Table 31 BIOPROJET PHARMAI: Major Product Offerings

Table 32 Bausch & Lomb: Major Product Offerings

Table 33 kal?o: Major Product Offerings

Table 34 Novartis: Major Product Offerings

Table 35 Global Epinephrine Auto-injectors Market by Dosage 2019?2025 (\$ million)

Table 36 Global Epinephrine Auto-injectors Market by Dosage 2019?2025 (%)

Table 37 Global Epinephrine Auto-injectors Market by Age Group 2019?2025 (\$ million)

Table 38 Global Epinephrine Auto-injectors Market by Age Group 2019?2025 (%)

Table 39 Global Epinephrine Auto-injectors Market by End-user 2019?2025 (\$ million)

Table 40 Global Epinephrine Auto-injectors Market by End-user 2019?2025 (%)

Table 41 Global Epinephrine Auto-injectors Market by Geography 2019?2025 (\$ million)

Table 42 Global Epinephrine Auto-injectors Market by Geography 2019?2025 (%)

Table 43 North America Epinephrine Auto-injectors Market by Dosage 2019?2025 (\$ million)

Table 44 North America Epinephrine Auto-injectors Market by Dosage 2019?2025 (%)

Table 45 Europe Epinephrine Auto-injectors Market by Dosage 2019?2025 (\$ million)

Table 46 Europe Epinephrine Auto-injectors Market by Dosage 2019?2025 (%)

Table 47 APAC Epinephrine Auto-injectors Market by Dosage 2019?2025 (\$ million)

Table 48 APAC Epinephrine Auto-injectors Market by Dosage 2019?2025 (%)

Table 49 Middle East & Africa Epinephrine Auto-injectors Market by Dosage 2019?2025 (\$ million)

Table 50 Middle East & Africa Epinephrine Auto-injectors Market by Dosage 2019?2025 (%)

Table 51 Latin America Epinephrine Auto-injectors Market by Dosage 2019?2025 (\$ million)

Table 52 Latin America Epinephrine Auto-injectors Market by Dosage 2019?2025 (%)

I would like to order

Product name: Epinephrine Auto-Injector Market - Global Outlook and Forecast 2020-2025

Product link: <https://marketpublishers.com/r/E9823EAAA5C7EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E9823EAAA5C7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970